Printer Friendly

DEL LABORATORIES CHANGES NAME OF SUBSIDIARY

 DEL LABORATORIES CHANGES NAME OF SUBSIDIARY
 FARMINGDALE, N.Y., Dec. 3 /PRNewswire/ -- Dan K. Wassong, chief


executive officer of Del Laboratories, Inc. (AMEX: DLI) of Farmingdale, N.Y. has announced that effective Dec. 1, 1991, it is changing the name of its pharmaceutical subsidiary, Commerce Drug Company, Inc., to Del Pharmaceuticals, Inc.
 "The change is being made in order to maximize the impact of the Del corporate name to the retail and wholesale trade, as well as the medical profession," said Charles J. Hinkaty, president of Del Pharmaceuticals, Inc.
 Commerce Drug Company, Inc., has been manufacturing and marketing over-the-counter drug products for over 50 years. It is best known for its Orajel and Propa pH product lines. The company was acquired by Del Laboratories, Inc. in 1963.
 For many years, Commerce Drug Company sales have consistently been growing at double digit rates. This growth can be attributed to several factors, including expanding the Orajel line with new formulations, increased advertising and promotion support, capitalizing on the potential of OTC pharmaceutical specialty brands like Stye and Boil Ease, and an aggressive new products program which generated Pronto Lice Control Treatment, Dermarest Anti-Itch Medication, Diaper Guard Diaper Rash Ointment, and Arthricare Topical Arthritis Pain Remedies.
 The executives who have guided the company's growth so successfully will continue in their posts. Del's management remains optimistic regarding the long-term growth potential of the rechristened subsidiary.
 -0- 12/3/91
 /CONTACT: Charles J. Hinkaty, president of Del Pharmaceuticals and Del International, 516-752-2056/
 (DLI) CO: Del Laboratories Inc.; Commerce Drug Company Inc. ST: New York IN: MTC SU: FC-OS -- NY037 -- 8734 12/03/91 11:53 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:271
Previous Article:JACLYN DECLARES CASH DIVIDEND
Next Article:/C O R R E C T I O N -- SIERRA ON-LINE/
Topics:


Related Articles
DEL LABORATORIES DECLARES DIVIDEND
DEL LABORATORIES, INC. REPORTS RESULTS
ITALIAN DRUG COMMITTEE DECISION LIKELY TO AFFECT INTERPHARM SALES
THE DUPONT MERCK PHARMACEUTICAL COMPANY FORMS A NEW GENERIC COMPANY, ENDO LABORATORIES L.L.C. AND NAMES CAROL A. AMMON PRESIDENT
ENDO LABORATORIES, L.L.C. INTRODUCES GENERIC CIMETIDINE
GLIPIZIDE TABLETS NOW AVAILABLE FROM ENDO LABORATORIES
DEL LABORATORIES, INC. REPORTS SECOND QUARTER RESULTS
Del Laboratories Reports First Quarter Earnings
Del Laboratories Announces Second Quarter and First Half Results
Mylan Announces Name Change for its Branded Products Subsidiary to Mylan Bertek.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters